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1129-199 Predictors of Adverse Events Complicating Carotid 
Artery Stenting in the Era of Distal Protection Devices 
Ramtin Aaah. Leslie Cho, Jacob Schneider, Albert W. Ghan. Marco Roffi, Christopher T. 
Bajzer, Jay S. Yadav, The Cleveland Clinic Foundation, Cleveland, OH 
Introduction: Despite the rapid acceptance of carotid stenting(CS) as an alternative to 
endarterectomy. little is known about clinical and angiographic predictors of poor out- 
come with CS in the current era. Methods: Using the data from our registry of 351 con- 
secutive patients who underwent CS between 1998 and 2001, we looked at 40 different 
clinical and angiographic variables to assess potential predictors of adverse events(AE). 
Majority of the patients in our registry had distal emboli protection devices used in con- 
junction with CS. Adverse events was defined as a combined endpoint of myccardial inf- 
arction, stroke, and death. Using multi-variate analysis, the predictors of AE peri- 
procedurally and at 6 months are shown. Resultsz The most significant predictors of 
peri-procedural AE were histoly of stroke, transient ischemic attack(TlA) and need for 
open heart surgery(pre-OHS). Also patients with COPD were at higher risk of events in 
our analysis. We found no association between patient’s age, lesion characteristics (cal- 
cification, morphology or diameter), contra-lateral carotid stenosis/occlusion and AE. At 6 
months, the predictors of poor outcome were low cardiac ejection fraction and diabetes. 
Conclusions: In the current era, patients who undergo CS with symptomatic lesions or 
are pm-OHS have higher peri-procedural AE; beyond the procedural period the tradi- 
tional risk factor for cardiovascular events, diabetes and low ejection fraction become 
more important predictor of events. 
Time-point Predictor P-value 
Peri-procedural Histoly of Stroke 0.0041 
History of TIA 0.049 
Pm-OHS 0.010 
6.months 
History of COPD 0.030 
Diabetes 0.048 
Baseline EF<30% 0.016 
1129-200 Chronic VisceraVMesenteric Ischemia: Role of 
Percutaneous Angioplasty and Stenting in Cellac and 
Mesenteric Artery Disease 
David E. Allie, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. 
Khan, Muhammad A. Khan, Peter S. Fail, Chris J. Hebert, Adam A. Allie, Craig M. 
Walker, Cardiovascular Institute of the South, Lafayette, LA, Columbia Medical Canter of 
Southwest Louisiana, Lafayette, LA 
Backaround: Surgical treatment for chronic mesenteric ischemia (CMI) is effective but 
technically demanding with operative mortality ranges from 3-14.7% (mean=7.5%) and 
morbidity ranges from E-44.7% (mean=28%). Percutaneolis transluminal angioplasty 
(PTA) alone for CMI is reported but has excessive recurrence rates (12.60%; 
mean=26%). Sparse data exists regarding indications, safety, feasibility, and durability of 
PTAlstenting for celiac and mesenteric artery disease. 
Methods: Between January 1998July 2002, 68 visceral artery stenosis [42 superior 
mesenteric (SMA) and 26 celiac artery (CA)] underwent PTAIstenting in 45 patients with 
CMI. A multivariable retrospective chart review was performed. Abdominal pain and 
weight loss wsre present in 41/45 (91%) and 39/45 (87%) respectively. An 8-French 
transfemoral approach was used in 30/42 (71%) SMA and 21/26 (80%) CA. A transbra- 
chial approach was required in 12/42 (29%) SMA and 5/20 (20%) CA. All patients 
received balloon expandable stems. 30168 (44%) vessels had 6 month duplex ultrasound 
(DU) and 25/88 (36%) angiography at median follow up of 23 months (range 7-54 
months). 
Results: Procedural success 67168 (98.5%) with 6 requiring a change from femoral to 
brachial access. No bowel infarction, stent thrombosis, or procedural deaths occurred. 
Pain relief improved in 38/42 (92%) and weight gain in 35139 (90%). 3/55 (5.4%) avail- 
able for objective follow-up developed restenosis (DU 2130 (6.6%) and angiography l/25 
(5%)] requiring repeat PTA/stenting for 100% primary assisted mid-term clinical succsss. 
There were no major complications requiring surgery and 2 minor access site hemato- 
mas (< 2 cm). 30.day mortality 0%. No late bowel related deaths. The l-year and P-year 
symptom free survival rates were 97.5% and 89.5% respectively. 
Conclusion: PTA/stenting for SMA and CA disease is a safe and effective treatment 
option for CMI offering excellent immediate and mid-term clinical succsss. 
1129-201 Bivalirudin as Sole Anticoagulant in Peripheral Vascular 
Disease: A Safety and Feasible Alternative in Renal and 
iliac Interventions 
David E. Allie, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. 
Khan, Muhammad A. Khan, Peter S. Fail, Chris J. Hebert, Adam A. Allie, Craig M. 
Walker, Cardiovascular Institute of the South, Lafayette, LA, Columbia Medical Center of 
Southwest Louisiana. Lafayette, LA 
Backaround: Many heparin limitations are Overcome by the direct thrombin inhibitor 
bivalirudin (Angiomax, The Medicines Company, Parsippany, NJ). Bivalirudin has shown 
a reduced incidence of ischemic and bleeding complications post percutaneous coronary 
interventions. The pharmacokinetic profile of bivalirudin appears well suited for percuta- 
neous peripheral intervention (PPf) yet few data exist regarding safety and feasibility in 
this setting. 
Methods: 180 renal and 75iliac PPl’s ware performed (May 2001-June 2002) with biva- 
lirudin as anticoagulation and compared to a historical heparin control (HC). Angiomax 
dose: 0.75 mglkg bolus with 1.75 mglkglhr infusion for procedural duration. Variables: 
Sheath removal time (SRT), access complication (AC), time to ambulate (TA), and length 
of stay (LOS). Follow up: 6 month renal and iliac duplex ultrasound. 
Rssultg No thrombotic events, intracranial bleeding, or major surgical complications 
occurred in bivalirudin group (BG). SRT, TA and LOS were reduced compared to HC 
(Table). 7/180 (3.8%) renal and 31’75 (4%) iliac required repeat PPI. 
Conclusion: Bivalirudin is a safe and feasible alternative anticoagulant in renal and iliac 
PPI and may offer decreased SRT, TA and LOS. Larger prospective randomized trials 
are warranted. 
Table 
Variables Ki 
Renal, 
I-l=180 
PPI success, ” 180 (100) 
(%) 
AC (Majorl), n 2(1.1) 
(%) 
AC (MinoR), 5(2.7) 
ll(%) 
SRT ~60 min, n 152 (84) 
(%) 
SRT >60 min, n 28 (16) 
(“@ 
LOS ~24 hrs, n 154(85.5) 
(%) 
LOS >24 hrs, ” 26(14.5) 
(%) 
TA <8 hrs, ” (“‘%) 136(75.5) 
TA >6 hrs, n (%) 44(24.5) 75 (42) 
HC Renal, 
n=l80 
179 (99) 
6 (3.3) 
8 (4.4) 
106 (59) 
74 (41) 
130 (72) 
50 (28) 
105 (58) 
P- Bc. HC Iliac 
VEdW Iliac n=75 
n=75 
0.3173 75 (100) 74 (98.6) 
0.1532 2(2.5) 3 (4) 
0.3974 3(4) 5 (6.6) 
<O.OOO 36 (48) 21 (28) 
1 
~0.000 39 (52) 54 (72) 
1 
0.002 42(56) 32 (43) 
0.002 33(44) 43(57) 
0.0005 31(41) 19 (25) 
0.0005 44(59) 56 (75) 
P- 
value 
0.317 
3 
0.650 
3 
0.468 
9 
0.011 
9 
0.011 
9 
0.103 
6 
0.103 
6 
0.038 
3 
0.038 
3 
l=“Major’ = any surgery, > 5 cm hematoma, or > 2u transfusion 
P=‘Minor’ = all other non-intracranial or retroperitoneal bleeding 
1129-202 Is Bivalirudin a Safe Alternative to Heparin During 
Carotid Stenting? A Case Matched Study 
Yuliva G. Adamvan, Gishel New, Sriram lyer, Thosaphol Limpijankit, Christina Brennan, 
Milena G. Adamian, Roxana Mehran, lzat Hjazi. Zoran Lasic, Sheriff Ibrahim, Jiri J. Vitek, 
Gary S. Roubin, Cardiovascular Research Foundation, New York, NY, Lenox Hill Heart 
and Vascular Institute, New York, NY 
Backaround: Previous studies have shown safetv and feasibilitv of the direct thrombin 
inhibitor Bivalirudin (B) during percutaneous coronary interventions. However, the safety 
txofile of this aaent as an alternative to unfractionated Heoann (UFH) durina carotid 
stenting (CS) is not known. 
_ 
Methods: From December 2001 to September 2002,59 consecutive pts (mean age = 72 
+ 9 yrs, 80.4% male) underwent CS with B and compared to 83 case matched controls 
receiving UFH during the same timeframe. B was administered in bolus dose of 0.75mgl 
kg, followed by drip (1.75 mg/kg/hr) throughout the procedure. 5,000 units of UFH were 
administered prior to the procedure in the UFH group. No GP Ilb/llla inhibitors were 
used. Neurological events, bleeding and vascular complications were recorded and adju- 
dicated by an independent committee. 
Results: Closure devices were used more often in B group than in UFH group (76.3% 
vs. 28.9% respectively, p< 0.0001). In-Hospital neurologic and vascular complications 
are shown in table. 
